170 results about "Extended release tablets" patented technology

The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable pH-independent polymers; d) one or more pharmaceutically acceptable acids; and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.

The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration C_max lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.

A single tablet layer having an extended release profile comparable to the release profile of a bi-layer tablet having both an immediate release and an extended release layer is prepared from a pharmaceutical granulation containing a pharmaceutically active compound, a hydrophilic polymer, and a water in-soluble, non-swellable particulate channeling agent.

A pharmaceutical composition includes micronized clarithromycin and exhibits improved dissolution characteristics relative to a pharmaceutical composition that includes unmicronized clarithromycin. The clarithromycin may have a particle size less than approximately 35 microns. One process for preparing an extended release tablet of the clarithromycin includes micronizing the clarithromycin; blending the micronized clarithromycin with one or more rate controlling polymers and pharmaceutically acceptable excipients; granulating the blend; and compressing to form a tablet. To treat a bacterial infection in a mammal in need of treatment, a patient may be administered a pharmaceutical composition that includes micronized clarithromycin.

An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer.

The invention is directed to the use of an extended release tablet formulation for pramipexole.

The invention belongs to the field of pharmaceutic preparations, and particularly provides a pramipexole dihydrochloride slow-release tablet with high content uniformity and a preparation method thereof. The invention provides the pramipexole dihydrochloride slow-release tablet which is independent of pH (potential of hydrogen) during drug release, is slowly released in buffer solutions with pHs of 1.2, 4.5 and 6.8 for 24 hours, reaches final release amounts above 85 percent without exception and only needs to be taken once every day. The preparation method provided by the invention is simple and practicable, relative standard deviations (RSDs) of the content uniformity and the release rate of the low-dose medicine, namely the pramipexole dihydrochloride can be guaranteed to be far below the RSD in a limit requirement, the between difference is small and the repeatability is high.

The invention provides clonidine hydrochloride sustained release tablets. The clonidine hydrochloride sustained release tablets are prepared from 0.2 part of clonidine hydrochloride, 70-90 parts of sustained release skeleton material and 10-20 parts of lubricating agent by weight. A preparation method of the clonidine hydrochloride sustained release tablets comprises the steps of material preparing, blending, granulating, blending, tabletting and aluminium-plastic packaging. The clonidine hydrochloride sustained release tablets and the preparation method have the beneficial effects that the clonidine hydrochloride sustained release tablets have good stability and definite curative effects and can be used for effectively treating hypertension; the novel sustained release preparations are adopted; sustained release refers to reducing the medicine release rates of medicines from the dosage forms and reducing the absorption rates of the medicines into bodies, thus achieving more stable treatment effects; compared with oral liquids, the clonidine hydrochloride sustained release tablets have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like; the preparation method is simple and practicable and is suitable for industrial production.

The invention discloses guanidine hydrochloride sustained release preparation and a preparation method thereof. The guanidine hydrochloride sustained release preparation is mainly prepared by guanidine hydrochloride, a filling agent, sustained release materials and potential of hydrogen (pH) sensitive materials. The preparation method comprises the steps of firstly preparing all raw materials according to proportion, evenly mixing the guanidine hydrochloride, the filling agent, the sustained release materials and the pH sensitive materials at high speed, granulating and drying the evenly mixed powder, finally adding a flow agent, a lubrication agent and an adhesion agent, tableting according to a general method, and achieving guanidine hydrochloride sustained release tablets. The guanidine hydrochloride sustained release preparation is small in side effect, obviously reduces difference of preparation of different batches, improves stability of samples, is convenient long term curing of patients and improves compliance of medicine. A patient can take the guanidine hydrochloride sustained release tablets once a day, so that effective drug concentration in bodies can be guaranteed for 24 hours, and nervous centralis side reactions caused by the fact that a blood concentration peak value is high due to general preparation is reduced.

This invention relates to an extended release tableted dosage formulation of the antidepressant venlafaxine hydrochloride or an optical form thereof having improved bioavailability.

The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.

The invention discloses a venlafaxine hydrochloride sustained-release tablet preparation which comprises venlafaxine hydrochloride, framework material, diluent, lubricant, adhesive and coating material. The experiments demonstrate that the venlafaxine hydrochloride sustained-release tablet achieves better sustained-release effect, can reduce the dosing frequency and is convenient for the patients to use. The invention also provides a preparation method thereof.

The invention provides a preparation method of compound ambroxol hydrochloride sustained release matrix tablet. The inventive ambroxol hydrochloride sustained release tablet specifically comprises (g/g) ambroxol hydrochloride 5-20%, roxithromycin 15-60%, skeletal material 5-40%, diluent 5-50%, pH regulator 0-20%, proper amount of binding agent, and proper amount of lubricant. The preparation method comprises mixing the materials and tabletting directly; or granulating part of the materials, mixing with the rest materials, mixing, and preparing into sustained release tablet; or mixing part of the raw materials with adjuvant, preparing into quick-release part, mixing the rest raw material, skeletal material, pH regulator and diluent as slow-released part, and preparing into double layer tablet with quick-release layer and sustained release layer. The method for preparing granulate comprises dry method, wet method, melting or fusion.

A slowly-releasing compound medicine in the form of tablet for treating and preventing thrombosis and apoplexy is prepared from aspirin, 2-(acetoxy) benzoic acid, slow-releasing dipyridamole, 2,2',2'',2''', [(4,8-dipiperidylpyrimido[5,4-d] pyrimidine-2,6-diyl) dihyponitido]-tetraethanol through granulating, tabletting and coating. Its advantages are high curative effect and equickly taking its effect.

The invention provides a metformin hydrochloride floating sustained-release tablet and a preparation method thereof. The metformin hydrochloride floating sustained-release tablet comprises a tablet core and a non-gastric-soluble coating film wrapped outside the tablet core, wherein the tablet core comprises metformin hydrochloride, a floating material, an adhesive and other excipients, and non-gastric-soluble coating film comprises a film forming material and other excipients. The tablet core is prepared by matching the above materials, and is matched with the non-gastric-soluble coating filmoutside the tablet core, and the density of the tablet core is less than 1g/cm<3>, so that the metformin hydrochloride floating sustained-release tablet can immediately float in water or gastric juice, thereby reducing the possibility of the tablet being discharged from the stomach into the duodenum, and prolonging the time in which the metformin hydrochloride sustained-release tablet floats in the stomach; the metformin hydrochloride floating sustained release tablet can float until the contents of the stomach are emptied, thereby ensuring that the medicine is released in the stomach; the metformin hydrochloride floating sustained-release tablet provided by the invention does not swell substantially in water or gastric juice, thereby reducing the possibility of abdominal distension feeling of a patient.

A modified release tablet of venlafaxine hydrochloride is formed by a core containing a lipophilic matrix and venlafaxine hydrochloride and a water-insoluble, permeable coating thereover.

The present invention relates to a metformin extended release tablet, particularly to a metformin extended release tablet comprising metformin, which is effective in treating non-insulin dependent diabetes mellitus, as active ingredient, and a matrix in which hydrophilic polymers and hydrophobic materials are mixed at a specific proportion. The hydrophilic polymers enable controlling of the pore size of the gel layer formed by water swelling, thereby enabling primary control of drug release rate. And, the hydrophobic materials block the pores of the gel layer, thereby enabling secondary control of drug release rate. Therefore, the metformin extended release tablet of the present invention has better dissolution properties than conventional extended release tablets and, thus, enables extended drug release at constant rate even with less matrix. A constant blood level can be maintained with one administration a day and the tablet can be made smaller, which makes the administration easier and the production simpler.

The invention discloses an extended action tablet containing metoprolol and a preparation method thereof. The drug mainly contains metoprolol, a hydrophobic retarding agent and a gel-type retarding agent. The invention enables the drug to achieve 24-hour slow release effect by mainly adopting a mode of taking the hydrophobic retarding agent and metoprolol as a binding agent after being dissolved or melted together; then mixing the binding agent and the gel-type retarding agent, pelletizing and tabletting. The extended action tablet has simple preparation process and high stability and is mainly used for treating high blood pressure.

The invention provides cyclobenzaprine hydrochloride sustained release tablets. The cyclobenzaprine hydrochloride sustained release tablets are prepared from 15 parts of cyclobenzaprine hydrochloride, 75-80 parts of sustained release skeleton material and 5-10 parts of lubricating agent by weight. A preparation method of the cyclobenzaprine hydrochloride sustained release tablets comprises the steps of material preparing, blending, granulating, blending, tabletting and aluminium-plastic packaging. The cyclobenzaprine hydrochloride sustained release tablets are adjuvant medicines for treating painful local muscle spasm and have the beneficial effects that the novel sustained release preparations are adopted; sustained release refers to reducing the medicine release rates of medicines from the dosage forms and reducing the absorption rates of the medicines into bodies, thus achieving more stable treatment effects; compared with oral liquids, the cyclobenzaprine hydrochloride sustained release tablets have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like. The preparation method is simple and practicable and is suitable for industrial production.

The invention discloses gliclazide sustained-release tablets, which are prepared by evenly mixing drug-loading particles with pharmaceutically acceptable adjuvant materials and tabletting the obtained mixture; a preparation method of the drug-loading particles comprises the following steps: heating glyceryl behenate up to 65-70 DEG C for melting, then adding meglumine and evenly stirring in a heat preservation process, adding gliclazide and stirring until the mixture is molten, cooling for solidifying, and pelletizing, wherein the mass ratio of the gliclazide to the glyceryl behenate to the meglumine is equal to 1 to (1.5-4.5) to (0.1-0.3). The gliclazide sustained-release tablets are stable in drug release speed, better in drug stability, high in bioavailability, simple in preparation technology and suitable for industrial mass production.